Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 56 clinical trials
featured
  • 0 views
  • 24 Jun, 2021
  • 1 location
featured
A Prospective, Randomized, Double-masked, Active Comparator-controlled, Multi-center, Two-arm, Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared With Intravitreal Aflibercept in Participants With Visual Impairment Due to Treatment-naïve Macular Edema Secondary to Retinal Vein Occlusion (RVO)

This Phase 3 study will evaluate the efficacy, durability, and safety of KSI-301 compared to aflibercept, in participants with macular edema due to treatment-naïve branch (BRVO) or central retinal

retinal vein occlusion
spectral domain optical coherence tomography
aflibercept
macular edema
  • 0 views
  • 24 Jun, 2021
  • 1 location
OPT-302 With Aflibercept in Neovascular Age-related Macular Degeneration (nAMD)

A 2-year phase 3, multicentre, randomised, parallel-group, sham-controlled, double-masked study. Primary efficacy will be determined at Week 52.

  • 3 views
  • 19 Sep, 2021
  • 62 locations
Study to Assess the Efficacy Safety and Tolerability of Intravitreal Aflibercept Compared to Laser Photocoagulation in Patients With Retinopathy of Prematurity

The primary objective of the study is to assess the efficacy of aflibercept compared to laser in patients diagnosed with retinopathy of prematurity (ROP). The secondary objectives of the study

  • 59 views
  • 30 May, 2021
  • 84 locations
Comparing Intravitreal Aflibercept Monotherapy vs Aflibercept Combined With Reduced Fluence PDT in PCV Treatment

In this study, we aim to evaluate the efficacy and safety of an individualized dosing schedule comprising Aflibercept and RF-PDT in patients with polypoidal choroidal vasculopathy (PCV). The

  • 0 views
  • 10 Jun, 2021
  • 3 locations
Treat-and-extend Using Aflibercept for Type 3 Neovascularization

Type 3 neovascularization is a subtype of neovascular age-related macular degeneration (AMD) that is characterized by intraretinal neovascularization. Treat-and-extend (TAE) regimen is a widely-used, effective anti-vascular endothelial growth factor treatment regimen for neovascular AMD, regardless of subtypes of AMD. The purpose of the present study is to investigate the 18-month …

  • 0 views
  • 04 Mar, 2021
  • 1 location
Plasma Biomarker for Aflibercept in Advanced Colorectal Cancer

Based on the pervious data, aflibercept in combination with FOLFIRI is one of the effective 2nd line treatment option in advanced colorectal cancer. In this study, we prospectively assess the

  • 0 views
  • 29 Mar, 2021
  • 1 location
To Compare Brolucizumab to Aflibercept in Chinese Patients With Visual Impairment Due to Diabetic Macular Edema

The purpose of this study is to evaluate the efficacy and safety of brolucizumab in treatment of Chinese patients with visual impairment due to Diabetic Macular Edema.

visual impairment
brolucizumab
diabetes
type 2 diabetes mellitus
aflibercept
  • 0 views
  • 14 Apr, 2021
  • 15 locations
Comparative Study of Dexamethasone Implant to Intravitreal Aflibercept in Subjects With Diabetic Macular Edema

This study is an interventional, prospective randomized study comparing the dexamethasone implant to intravitreal aflibercept. Subjects will have an initial single injection of aflibercept and

retinal edema
edema secondary
visual impairment
retinopathy
dexamethasone
  • 0 views
  • 31 Jul, 2021
  • 1 location
Interval of Disease Inactivity After Complete Polypoidal Regression in PCV Receiving Aflibercept

outcome in large PCV trials including the PLANET1 and EVEREST II2 studies. Rate of polypoidal regression following intravitreous aflibercept monotherapy was 33% in the PLANET study1 year 2 and ranged

  • 0 views
  • 28 Jan, 2021
  • 1 location